Computational Algorithm-Driven Evaluation of Monocytic Myeloid-Derived Suppressor Cell Frequency for Prediction of Clinical Outcomes
Shigehisa Kitano, Michael Andrew Postow, Carly G.K. Ziegler et al. · Cancer Immunology Research · 2014
Evaluation of myeloid-derived suppressor cells (MDSC), a cell type implicated in T-cell suppression, may inform immune status. However, a uniform methodology is necessary for prospective testing as a biomarker. We report the use of a computational algorithm-driven analysis of whole blood and cryopreserved samples for monocytic MDSC (m-MDSC) quantity that removes variables related to blood processing and user definitions. Applying these methods to samples from patients with melanoma identifies differing frequency distribution of m-MDSC relative to that in healthy donors. Patients with a pretreatment m-MDSC frequency outside a preliminary definition of healthy donor range (<14.9%) were significantly more likely to achieve prolonged overall survival following treatment with ipilimumab, an antibody that promotes T-cell activation and proliferation. m-MDSC frequencies were inversely correlated with peripheral CD8(+) T-cell expansion following ipilimumab. Algorithm-driven analysis may enable not only development of a novel pretreatment biomarker for ipilimumab therapy, but also prospective validation of peripheral blood m-MDSCs as a biomarker in multiple disease settings.
Cited by 134 works. doi:10.1158/2326-6066.cir-14-0013 Open-access PDF
Authors
- Shigehisa Kitano
- Michael Andrew Postow
- Carly G.K. Ziegler
- Deborah Kuk
- Katherine S. Panageas
- Czrina A. Cortez
- Teresa S. Rasalan
- Matthew J. Adamow
- Jianda D. Yuan
- Phillip Y.-P. Wong
- Grégoire Y Altan-Bonnet
- Jedd D. Wolchok
- Alexander M. Lesokhin
References
- PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- Myeloid-derived suppressor cells as regulators of the immune system
- Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
- Coordinated regulation of myeloid cells by tumours
- Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
- Single‐institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting
- An immune-active tumor microenvironment favors clinical response to ipilimumab
- Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials